GABA

Function

Neurotransmitter

Two general classes of GABA receptor are known:

• GABAA in which the receptor is part of a ligand-gated ion channel complex
• GABAB metabotropic receptors, which are G protein-coupled receptors that open or close ion channels via intermediaries (G proteins)

Neurons that produce GABA as their output are called GABAergic neurons. In adult vertebrates, GABA is usually considered as the major inhibitory neurotransmitter. It also exhibits excitatory effect via GABAB receptor, in which case, a specific type of voltage dependent calcium channel is activated.

Medium spiny cells are a typical example of inhibitory central nervous system GABAergic cells. In contrast, GABA exhibits both excitatory and inhibitory actions in insects, mediating muscle activation at synapses between nerves and muscle cells, and also the stimulation of certain glands. In mammals, some GABAergic neurons, such as chandelier cells, are also able to excite their glutamatergic counterparts. In addition to fast-acting phasic inhibition, small amounts of extracellular GABA can induce slow timescale tonic inhibition on neurons.

GABAA receptors are ligand-activated chloride channels: when activated by GABA, they allow the flow of chloride ions across the membrane of the cell. Whether this chloride flow is depolarizing (makes the voltage across the cell's membrane less negative), shunting (has no effect on the cell's membrane potential), or inhibitory/hyperpolarizing (makes the cell's membrane more negative) depends on the direction of the flow of chloride. When net chloride flows out of the cell, GABA is depolarising; when chloride flows into the cell, GABA is inhibitory or hyperpolarizing. When the net flow of chloride is close to zero, the action of GABA is shunting. Shunting inhibition has no direct effect on the membrane potential of the cell; however, it reduces the effect of any coincident synaptic input by reducing the electrical resistance of the cell's membrane.

Shunting inhibition can "override" the excitatory effect of depolarising GABA, resulting in overall inhibition even if the membrane potential becomes less negative. It was thought that a developmental switch in the molecular machinery controlling the concentration of chloride inside the cell changes the functional role of GABA between neonatal and adult stages. As the brain develops into adulthood, GABA's role changes from excitatory to inhibitory.

Brain development

GABA is an inhibitory transmitter in the mature brain; its actions were thought to be primarily excitatory in the developing brain. The gradient of chloride was reported to be reversed in immature neurons, with its reversal potential higher than the resting membrane potential of the cell; activation of a GABA-A receptor thus leads to efflux of Cl− ions from the cell (that is, a depolarizing current). The differential gradient of chloride in immature neurons was shown to be primarily due to the higher concentration of NKCC1 co-transporters relative to KCC2 co-transporters in immature cells. GABAergic interneurons mature faster in the hippocampus and the GABA machinery appears earlier than glutamatergic transmission. Thus, GABA is considered the major excitatory neurotransmitter in many regions of the brain before the maturation of glutamatergic synapses.

In the developmental stages preceding the formation of synaptic contacts, GABA is synthesized by neurons and acts both as an autocrine (acting on the same cell) and paracrine (acting on nearby cells) signalling mediator. The ganglionic eminences also contribute greatly to building up the GABAergic cortical cell population.

GABA regulates the proliferation of neural progenitor cells, the migration and differentiation the elongation of neurites and the formation of synapses.

GABA also regulates the growth of embryonic and neural stem cells. GABA can influence the development of neural progenitor cells via brain-derived neurotrophic factor (BDNF) expression. GABA activates the GABAA receptor, causing cell cycle arrest in the S-phase, limiting growth.

Beyond the nervous system

Besides the nervous system, GABA is also produced at relatively high levels in the insulin-producing beta cells (β-cells) of the pancreas. The β-cells secrete GABA along with insulin and the GABA binds to GABA receptors on the neighboring islet alpha cells (α-cells) and inhibits them from secreting glucagon (which would counteract insulin's effects).

GABA can promote the replication and survival of β-cells and also promote the conversion of α-cells to β-cells, which may lead to new treatments for diabetes.

Alongside GABAergic mechanisms, GABA has also been detected in other peripheral tissues including intestines, stomach, fallopian tubes, uterus, ovaries, testicles, kidneys, urinary bladder, the lungs and liver, albeit at much lower levels than in neurons or β-cells.

Experiments on mice have shown that hypothyroidism induced by fluoride poisoning can be halted by administering GABA. The test also found that the thyroid recovered naturally without further assistance after the fluoride had been expelled by the GABA.

Immune cells express receptors for GABA and administration of GABA can suppress inflammatory immune responses and promote "regulatory" immune responses, such that GABA administration has been shown to inhibit autoimmune diseases in several animal models.

In 2018, GABA was shown to regulate secretion of a greater number of cytokines. In plasma of T1D patients, levels of 26 cytokines are increased and of those, 16 are inhibited by GABA in the cell assays.

In 2007, an excitatory GABAergic system was described in the airway epithelium. The system is activated by exposure to allergens and may participate in the mechanisms of asthma. GABAergic systems have also been found in the testis and in the eye lens.

Structure and conformation

GABA is found mostly as a zwitterion (i.e., with the carboxyl group deprotonated and the amino group protonated). Its conformation depends on its environment. In the gas phase, a highly folded conformation is strongly favored due to the electrostatic attraction between the two functional groups. The stabilization is about 50 kcal/mol, according to quantum chemistry calculations. In the solid state, an extended conformation is found, with a trans conformation at the amino end and a gauche conformation at the carboxyl end. This is due to the packing interactions with the neighboring molecules. In solution, five different conformations, some folded and some extended, are found as a result of solvation effects. The conformational flexibility of GABA is important for its biological function, as it has been found to bind to different receptors with different conformations. Many GABA analogues with pharmaceutical applications have more rigid structures in order to control the binding better.

History

GABA was first synthesized in 1883; it was first known only as a plant and microbe metabolic product.

In 1950, Washington University School of Medicine researchers Eugene Roberts and Sam Frankel used newly-developed techniques of chromatography to analyze protein-free extracts of mammalian brain. They discovered that GABA is metabolized from glutamic acid and accumulates in the mammalian central nervous system.

There was not much further research into the substance until 1957; Canadian researchers identified GABA as the mysterious component (termed Factor I by its discoverers in 1954) of brain and spinal cord extracts which inhibited crayfish neurons.

In 1959, it was shown that, at an inhibitory synapse on crayfish muscle fibers, GABA acts through stimulation of the inhibitory nerve. Both inhibition by nerve stimulation and by applied GABA are blocked by picrotoxin.

Biosynthesis

GABA is primarily synthesized from glutamate via the enzyme glutamate decarboxylase (GAD) with pyridoxal phosphate (the active form of vitamin B6) as a cofactor. This process converts glutamate (the principal excitatory neurotransmitter) into GABA (the principal inhibitory neurotransmitter).

GABA can also be synthesized from putrescine by diamine oxidase and aldehyde dehydrogenase.

Historically it was thought that exogenous GABA did not penetrate the blood–brain barrier, but more current research describes the notion as being unclear pending further research.

Metabolism

GABA transaminase enzymes catalyze the conversion of 4-aminobutanoic acid (GABA) and 2-oxoglutarate (α-ketoglutarate) into succinic semialdehyde and glutamate. Succinic semialdehyde is then oxidized into succinic acid by succinic semialdehyde dehydrogenase and as such enters the citric acid cycle as a usable source of energy.

Pharmacology

Drugs that act as allosteric modulators of GABA receptors (known as GABA analogues or GABAergic drugs), or increase the available amount of GABA, typically have relaxing, anti-anxiety, and anti-convulsive effects (with equivalent efficacy to lamotrigine based on studies of mice). Many of the substances below are known to cause anterograde amnesia and retrograde amnesia.

In general, GABA does not cross the blood–brain barrier, although certain areas of the brain that have no effective blood–brain barrier, such as the periventricular nucleus, can be reached by drugs such as systemically injected GABA. GABA directly injected to the brain has been reported to have both stimulatory and inhibitory effects on the production of growth hormone, depending on the physiology of the individual. Consequently, considering the potential biphasic effects of GABA on growth hormone production, as well as other safety concerns, its usage is not recommended during pregnancy and lactation.

GABA enhances the catabolism of serotonin into N-acetylserotonin (the precursor of melatonin) in rats. It is thus suspected that GABA is involved in the synthesis of melatonin and thus might exert regulatory effects on sleep and reproductive functions.

GABA and anesthetics

Lots of general anesthetics work by changing how GABA acts in the brain. Drugs such as propofol, etomidate, barbiturates, and many gases like isoflurane and sevoflurane cause GABAa receptors to become more active. When these receptors become more active, GABA open chloride channels for a longer time, which causes nerve cells to be less likely to send signals. GABAa receptors can become desensitized to GABA and stop opening when the ligand is attached. Anesthetics work in two main ways: enhancing the effectiveness of GABA molecules, and manipulating the GABAa receptor to become less susceptible to desensitization. The slowing of brain activity from increased chloride movement causes the body to calm down, become drowsy, and eventually end up in an unconscious state that is needed for surgery. Some anesthetics can even activate GABAa receptors without GABA even being present. The various types of GABA receptors have drug specific reactions which cause the differing effects of anesthetics.

Chemistry

Although in chemical terms, GABA is an amino acid (as it has both a primary amine and a carboxylic acid functional group), it is rarely referred to as such in the professional, scientific, or medical community. By convention the term "amino acid", when used without a qualifier, refers specifically to an alpha amino acid. GABA is not an alpha amino acid, meaning the amino group is not attached to the alpha carbon. Nor is it incorporated into proteins as are many alpha-amino acids.

GABAergic drugs

GABAA receptor ligands are shown in the following table.

GABAergic pro-drugs include chloral hydrate, which is metabolised to trichloroethanol, which then acts via the GABAA receptor.

The plant kava contains GABAergic compounds, including kavain, dihydrokavain, methysticin, dihydromethysticin and yangonin.

Other GABAergic modulators include:

• GABAB receptor ligands.
  • Agonists: baclofen, propofol, GHB, phenibut.
  • Antagonists: phaclofen, saclofen.
• GABA reuptake inhibitors: deramciclane, hyperforin, tiagabine.
• GABA transaminase inhibitors: gabaculine, phenelzine, valproate, vigabatrin, lemon balm (Melissa officinalis).
• GABA analogues: pregabalin, gabapentin, picamilon, progabide

4-Amino-1-butanol is a biochemical precursor of GABA and can be converted into GABA by the actions of aldehyde reductase (ALR) and aldehyde dehydrogenase (ALDH) with γ-aminobutyraldehyde (GABAL) as a metabolic intermediate.

In plants

GABA is also found in plants. It is the most abundant amino acid in the apoplast of tomatoes. Evidence also suggests a role in cell signalling in plants. Recently, a new enzyme technology has been developed to enhance the GABA content of protein-rich seeds such as Andean lupine or tarwi (Lupinus mutabilis) and varieties of quinoa (Chenopodium quinoa) and its relative, cañahua (Chenopodium pallidicaule).

Notes

References

References

1. (2016). "CRC Handbook of Chemistry and Physics". [[CRC Press]].
2. "SDS - Gamma-aminobutyric acid".
3. "Human Metabolome Database - Gamma-aminobutyric acid".
4. (2013-03-08). "Generalized Non-Convulsive Epilepsy: Focus on GABA-B Receptors". Springer Science & Business Media.
5. (2018-07-25). "Cryo-EM structure of the benzodiazepine-sensitive α1β1γ2S tri-heteromeric GABA_A receptor in complex with GABA". eLife.
6. (July 2016). "Presynaptic Excitation via GABA B Receptors in Habenula Cholinergic Neurons Regulates Fear Memory Expression". Cell.
7. (June 1993). "A point mutation in a ''Drosophila'' GABA receptor confers insecticide resistance". Nature.
8. (January 2006). "Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits". Science.
9. (2023-07-26). "GABA tone regulation and its cognitive functions in the brain". Nature Reviews Neuroscience.
10. (June 2008). "The role and the mechanism of γ-aminobutyric acid during central nervous system development". Neurosci Bull.
11. (October 2007). "GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations". Physiol. Rev..
12. (2016-11-25). "The Glutamate/GABA-Glutamine Cycle: Amino Acid Neurotransmitter Homeostasis". Springer.
13. (2007). "Neuroscience". Sinauer.
14. (2005). "GABA in Autism and Related Disorders".
15. (November 2001). "A long, remarkable journey: tangential migration in the telencephalon". Nat. Rev. Neurosci..
16. (December 1995). "GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis". Neuron.
17. (August 2000). "Differential modulation of proliferation in the neocortical ventricular and subventricular zones". J. Neurosci..
18. (August 1998). "Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus". J. Neurosci..
19. (May 2001). "GABA itself promotes the developmental switch of neuronal GABAergic responses from excitation to inhibition". Cell.
20. (April 1993). "Involvement of GABAA receptors in the outgrowth of cultured hippocampal neurons". Neurosci. Lett..
21. (April 2001). "GABA expression dominates neuronal lineage progression in the embryonic rat neocortex and facilitates neurite outgrowth via GABA(A) autoreceptor/Cl⁻ channels". J. Neurosci..
22. (September 2002). "Excitatory actions of gaba during development: the nature of the nurture". Nat. Rev. Neurosci..
23. (August 2002). "Excitatory actions of GABA increase BDNF expression via a MAPK-CREB-dependent mechanism—a positive feedback circuit in developing neurons". J. Neurophysiol..
24. (2008). "GABA regulates stem cell proliferation before nervous system formation". Epilepsy Curr.
25. (2009). "Adult and embryonic GAD transcripts are spatiotemporally regulated during postnatal development in the rat brain". [[PLoS ONE]].
26. (1989). "Glucose-inhibition of glucagon secretion involves activation of GABA_A-receptor chloride channels". Nature.
27. (2011). "GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes". Proc. Natl. Acad. Sci. U.S.A..
28. (2013). "γ-Aminobutyric acid regulates both the survival and replication of human β-cells". Diabetes.
29. (2014). "GABA promotes human β-cell proliferation and modulates glucose homeostasis". Diabetes.
30. (2017). "Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis". Cell.
31. (February 1990). "γ-Aminobutyric acid outside the mammalian brain". J. Neurochem..
32. (2016). "γ-Aminobutyric acid ameliorates fluoride-induced hypothyroidism in male Kunming mice". Life Sciences.
33. (1999). "GABA_A receptors mediate inhibition of T cell responses". J. Neuroimmunol..
34. (2012). "Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes". PLOS ONE.
35. (2004). "Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model". J. Immunol..
36. (2011). "Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis". Autoimmunity.
37. (April 2018). "+ T Cells and Is Immunosuppressive in Type 1 Diabetes". eBioMedicine.
38. (July 2007). "A GABAergic system in airway epithelium is essential for mucus overproduction in asthma". Nat. Med..
39. (2007). "The Leydig cell in health and disease". Humana Press.
40. (December 2007). "GAD isoforms exhibit distinct spatiotemporal expression patterns in the developing mouse lens: correlation with Dlx2 and Dlx5". Dev. Dyn..
41. (1988). "Conformation, electrostatic potential and pharmacophoric pattern of GABA (γ-aminobutyric acid) and several GABA inhibitors". Journal of Molecular Structure: THEOCHEM.
42. (May 2013). "Molecular Orbital Calculations for Amino Acids and Peptides". Birkhäuser.
43. (2003). "The Biochemical Basis of Neuropharmacology". Oxford University Press.
44. Spiering, Martin J.. (December 2018). "The discovery of GABA in the brain". Journal of Biological Chemistry.
45. (November 1950). "gamma-Aminobutyric acid in brain: its formation from glutamic acid". The Journal of Biological Chemistry.
46. (August 1957). "Isolation of Factor I". Journal of Neurochemistry.
47. (1959). "The effects of GABA and picrotoxin on the junctional potential and the contraction of crayfish muscle". Experientia.
48. (December 2002). "GABA and glutamate in the human brain". Neuroscientist.
49. (2007). "Gaba and the Basal Ganglia - from Molecules to Systems".
50. Krantis, Anthony. (2000-12-01). "GABA in the Mammalian Enteric Nervous System". Physiology.
51. (2007-05-11). "Putrescine as an important source of GABA in the postnatal rat subventricular zone". Neuroscience.
52. (January 1971). "Blood–brain barrier to H3-γ-aminobutyric acid in normal and amino oxyacetic acid-treated animals". Neuropharmacology.
53. (2015). "Neurotransmitters as food supplements: the effects of GABA on brain and behavior". Front Psychol.
54. (September 1997). "The Metabolism and Functions of γ-Aminobutyric Acid". Plant Physiol..
55. (February 2006). "Glutamate- and GABA-based CNS therapeutics". Curr Opin Pharmacol.
56. (October 2001). "A pharmacological link between epilepsy and anxiety?". Trends Pharmacol. Sci..
57. (May 2003). "Mechanisms of actions of inhaled anesthetics". N. Engl. J. Med..
58. (January 2008). "Growth hormone isoform responses to GABA ingestion at rest and after exercise". Medicine and Science in Sports and Exercise.
59. (April 1999). "Neuroendocrine control of growth hormone secretion". Physiol. Rev..
60. (August 2021). "United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA)". Nutrients.
61. (1983). "The influence of GABA on the synthesis of N-acetylserotonin, melatonin, O-acetyl-5-hydroxytryptophol and O-acetyl-5-methoxytryptophol in the pineal gland of the male Wistar rat". Reproduction, Nutrition, Development.
62. (2008). "Sexually dimorphic modulation of GABA(A) receptor currents by melatonin in rats gonadotropin–releasing hormone neurons". The Journal of Physiological Sciences.
63. (1998-11-23). "General anaesthetics and their effects on GABAA receptor desensitization". Toxicology Letters.
64. (Oct 2017). "The Role of GABA Receptor Agonists in Anesthesia and Sedation". CNS Drugs.
65. (2013-06-01). "Potentiation of GABAA receptor activity by volatile anaesthetics is reduced by α5GABAA receptor-preferring inverse agonists". British Journal of Anaesthesia.
66. Hellier, Jennifer L.. (2014-12-16). "The Brain, the Nervous System, and Their Diseases [3 volumes]". ABC-CLIO.
67. (2017). "GABAA Receptors and the Diversity in their Structure and Pharmacology".
68. (2012). "How theories evolved concerning the mechanism of action of barbiturates". Epilepsia.
69. (2006). "Basic Neurochemistry: Molecular, Cellular and Medical Aspects". Elsevier.
70. Toraskar, Mrunmayee. (2010). "Study of GABAergic Agonists". Deccan Journal of Pharmacology.
71. (2008). "Modern Anesthetics".
72. (2003). "γ-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in ''Drosophila'': adult RNA interference and pharmacological evidence". Proc. Natl. Acad. Sci. U.S.A..
73. (1997). "Sites of alcohol and volatile anaesthetic action on GABA_A and glycine receptors". Nature.
74. (January 2009). "The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator". Neuropharmacology.
75. (1997). "Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor". The Journal of Neuroscience.
76. Olsen RW. (April 2000). "Absinthe and gamma-aminobutyric acid receptors". Proc. Natl. Acad. Sci. U.S.A..
77. (1995-01-01). "Pharmacology of flumazenil". Acta Anaesthesiologica Scandinavica. Supplementum.
78. "Chloroacetaldehydes".
79. (2006). "Sleep circuitry and the hypnotic mechanism of GABA_A drugs". Journal of Clinical Sleep Medicine.
80. (2002). "Therapeutic potential of kava in the treatment of anxiety disorders". CNS Drugs.
81. (2005). "''Drosophila'' GABA_B receptors are involved in behavioral effects of gamma-hydroxybutyric acid (GHB)". Eur. J. Pharmacol..
82. (August 2009). "Bioassay-guided fractionation of lemon balm (''Melissa officinalis'' L.) using an in vitro measure of GABA transaminase activity". Phytother Res.
83. (2011). "Gabapentin, A GABA analogue, enhances cognitive performance in mice". Neuroscience Letters.
84. (10 October 1997). "Polyamine Protocols". Humana Press.
85. (2015). "GABA signalling modulates plant growth by directly regulating the activity of plant-specific anion transporters". Nat Commun.
86. (2016). "γ-Aminobutyric acid (GABA) signalling in plants". Cell. Mol. Life Sci..
87. (October 2010). "Mutations in γ-aminobutyric acid (GABA) transaminase genes in plants or ''Pseudomonas syringae'' reduce bacterial virulence". Plant J..
88. (March 2004). "GABA in plants: just a metabolite?". Trends Plant Sci..
89. (September 2007). "Does GABA Act as a Signal in Plants?: Hints from Molecular Studies". Plant Signal Behav.
90. (March 2025). "Enhancing the functional value of Andean food plants: Enzymatic production of γ-aminobutyric acid from tarwi, cañihua and quinoa real seeds' proteins". LWT.